Veradermics, Inc. (MANE)
102.23
+3.77
(+3.83%)
USD |
NYSE |
Aug 25, 16:00
102.23
0.00 (0.00%)
After-Hours: 19:25
Veradermics Debt to Equity Ratio : 0.0005 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0005 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Eli Lilly & Co. | 1.621 |
| EyePoint, Inc. | 0.1344 |
| Elanco Animal Health, Inc. | 0.5947 |
| Tarsus Pharmaceuticals, Inc. | 0.2557 |
| Amylyx Pharmaceuticals, Inc. | 0.022 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 826.33M |
| Total Liabilities (Quarterly) | 12.12M |
| Shareholders Equity (Quarterly) | 814.21M |
| Current Ratio | 70.53 |
| Net Debt Paydown Yield | -0.00% |